Vivalis was founded in 1999 with the aim to better understand the extraordinary biological properties of embryonic stem (ES) cells and to use this knowledge for practical applications in human and animal health. The company’s distinctive expertise in the field of avian ES cells has led to the development and successful commercialization of its proprietary EB66® platform, derived from duck embryonic stem cells, which has shown high utility in the production of human vaccines and monoclonal antibodies requiring enhanced ADCC.
Vivalis also performs CMO services for the GMP manufacture of vaccines and antibodies/non-antibody proteins. Our facility has been inspected by l'AFSSAPS for up to Phase II production of materials used in human clinical trials. Whether produced in Vivalis's EB66 platform or another cell line, the GMP facility is platform-neutral so products and cell lines of multiple origin can be utilized.
Is this your Organization? Request Access
Locations
Building A
6, rue Alain Bombard
Saint-Herblain,
44821
France,
Europe
GMP Experience
Two independent production trains that have been inspected and authorized by l'AFSSAPS, the French Medicines Agency for the production of Investigational Medicinal Products.